$NBIO A third payment of USD $2,500,000 will be re
Post# of 12184
![](/assets/46931549/no_avatar_available_thumb.jpg)
Quote:
A third payment of USD $2,500,000 will be received by Nascent upon approval from the FDA to conduct a Phase 2 clinical trial of Pritumumab.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)
Quote:
A third payment of USD $2,500,000 will be received by Nascent upon approval from the FDA to conduct a Phase 2 clinical trial of Pritumumab.